Medical University Graz, Division of Pulmonology
Graz, Styria, 8010, Austria
NCT Number: NCT01607489
The aim of the study is to determine relevant hemodynamic parameters for the diagnostics of pulmonary arterial hypertension (PAH) by dynamic contrast enhanced dual-energy CT (DE-CT). In this pilot study the investigators investigate patients who underwent right heart catheterisation with DE-CT to determine hemodynamic parameters and control the results by other clinical investigations. The investigators expect that using this non-invasive method, parameters relevant for the diagnosis of the patients with PAH, like pulmonary blood volume, blood flow and perfusion heterogeneity, can be determined.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Graz, Styria, 8010, Austria
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disease. It is characterized by the elevation of pulmonary arterial pressure and pulmonary vascular resistance. A remodeling of small pulmonary vessels characterized by the proliferation of the adventitia, the hypertrophy of the media and fibrosis of the intima can be observed on the microscopic level.
Non-invasive techniques for hemodynamic assessment and identification of early pulmonary vascular remodeling and pulmonary hypertension have a marked practical advantage as compared to invasive right heart catheterization, however, their accuracy and reliability is not well established.
In the present study the investigators examine patients who underwent right heart catheterization and are scheduled for a thorax CT with an additional dynamic contrast-enhanced DE-CT protocol and derive established parameters for the diagnosis of PAH as well as novel parameters from the CT scans. These are compared to results from the right-heart catheterization and other investigations routinely carried out on these patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1x 20ml Ultravist (370mg J/ml)3-5ml/s,
1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration
Other names: CT
Time frame: measurements with right heart catheterisation within 1 month
determination of differences in pulmonary blood flow and volume of pulmonary hypertension patients
Time frame: measurements with right heart catheterisation within 1 month
comparison of different state or type of pulmonary hypertension
Time frame: measurements with right heart catheterisation within 1 month
quantification of regional perfusion differences in pulmonary hypertension patients
Medical University of Graz
Other
Non-invasive Diagnostics of Pulmonary Hypertension With Dual Energy Computed Tomography - Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03893500
Hypertension, Pulmonary, Lung Diseases
Stanford, California, United States
View Trial DetailsNCT05679570
Hypertension, Pulmonary, Lung Diseases
Kagoshima, Kagoshima-ken, Japan
View Trial DetailsNCT04266197
Hypertension, Pulmonary, Lung Diseases
Birmingham, Alabama, United States
View Trial DetailsNCT02845518
Cardiovascular Diseases, Hypertension
Vandœuvre-lès-Nancy, France
View Trial Details